Insmed (INSM) in Focus: Stock Moves 7.1% Higher
Insmed Incorporated INSM was a big mover last session, as the company saw its shares rise more than 7% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $16.12 –$18.30 in the past one-month time frame, witnessed a sharp increase yesterday.
The company has seen one positive estimate revisions in the past few weeks, while its Zacks Consensus Estimate for the current quarter has also moved higher over the past few weeks, suggesting that more solid trading could be ahead for Insmed. So make sure to keep an eye on this stock going forward to see if this recent jump can turn into more strength down the road.
Insmed currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Insmed, Inc. Price
Investors interested in the Medical – Biomedical and Genetics industry may consider Acorda Therapeutics, Inc. ACOR, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is INSM going up? Or down? Predict to see what others think:Up or Down
Free: Zacks’ Single Best Stock Set to Double
Today you are invited to download our just-released Special Report that reveals 5 stocks with the most potential to gain +100% or more in 2020. From those 5, Zacks Director of Research, Sheraz Mian hand-picks one to have the most explosive upside of all.
This pioneering tech ticker had soared to all-time highs and then subsided to a price that is irresistible. Now a pending acquisition could super-charge the company’s drive past competitors in the development of true Artificial Intelligence. The earlier you get in to this stock, the greater your potential gain.
Download Free Report Now >>
Click to get this free report
Acorda Therapeutics, Inc. (ACOR): Free Stock Analysis Report
Insmed, Inc. (INSM): Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.